Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Clinical Genitourinary Cancer|June 10, 2023
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchHedyeh Ebrahimi, Daniela V Castro, Matthew I Feng, et al.
Cancer Medicine|March 27, 2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and InclusionBenjamin D Mercier, Ameish Govindarajan, Daniela V Castro, et al.
BJU International|August 7, 2023
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapyDaniela V Castro, Sweta R Prajapati, Matthew I Feng, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
Pageof 5